Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Merkel Cell 6Neoplasm Metastasis 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Urethral Neoplasms 1Ureteral Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Penile Squamous Cell Carcinoma (PSCC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × avelumab × 90 days × Clear all
NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT03815643 2026-03-31

Avelumab Program Rollover Study

EMD Serono

Phase 3 Active not recruiting
205 enrolled
GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡